ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain Sells 1,373 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vivek Jain also recently made the following trade(s):

• On Monday, December 2nd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00.
• On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00.

ICU Medical Stock Up 1.8 %

NASDAQ ICUI opened at $157.98 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market cap of $3.87 billion, a price-to-earnings ratio of -34.57 and a beta of 0.62. The company has a 50 day moving average of $164.56 and a 200-day moving average of $155.51. ICU Medical, Inc. has a 1-year low of $86.80 and a 1-year high of $196.26.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ICUI shares. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, KeyCorp upped their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $199.67.

Hedge Funds Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICUI. Principal Financial Group Inc. increased its position in shares of ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after purchasing an additional 25,031 shares during the period. Franklin Resources Inc. increased its holdings in ICU Medical by 99.3% in the 3rd quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock valued at $2,111,000 after buying an additional 5,834 shares during the period. Coldstream Capital Management Inc. acquired a new position in shares of ICU Medical in the 3rd quarter valued at approximately $227,000. Geode Capital Management LLC lifted its holdings in shares of ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after acquiring an additional 48,106 shares during the period. Finally, Barclays PLC boosted its position in shares of ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.